
Johnson & Johnson announced Monday it has entered into a definitive agreement to acquire Ollin Biosciences, the Austin-based biotech behind a late-stage experimental treatment for eye diseases, in a deal worth up to $3.3 billion. The agreement calls for $2.2 billion upfront, with the potential for an additional roughly $1.125 billion tied to regulatory and commercial milestones.
The pharmaceutical giant's announcement, detailed in a Johnson & Johnson press release, frames the acquisition around Ollin's lead program, OLN324, described as a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema. The deal is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions — meaning it has not yet been finalized.
Ollin Biosciences was founded in 2023 but only came out of stealth mode last year, according to the Austin Business Journal. The company's launch announcement, made in September 2025, introduced it with an initial $100 million in financing and named Jason Ehrlich, M.D., Ph.D., as co-founder and CEO.
From Stealth Launch to Oversubscribed Series B
Ollin's rise from relative obscurity to a multibillion-dollar acquisition target happened quickly. The company disclosed an oversubscribed $330 million Series B financing round in June, money earmarked to advance global Phase 3 development of OLN324 in studies for diabetic macular edema and wet age-related macular degeneration that were set to begin in the second half of this year, per Ollin's own announcement.
Industry outlet Endpoints News also covered the deal, reporting the same up to $3.3 billion figure tied to J&J's bid for the eye disease biotech. The pairing of a major Series B raise with a fast-tracked acquisition less than five months later underscores how quickly investor interest can translate into a buyout in the biotech sector.
Part of a Booming Local Industry
Ollin's trajectory lands against the backdrop of a fast-growing Austin bio and health sector. A 2024 report cited by the Austin Monitor found more than 1,100 bio and health companies in the city, employing 21,000 people and generating a combined ecosystem valuation of $42 billion. The same report found the sector had raised $3.5 billion in venture capital over the preceding five years, with 40 Austin bio and health companies valued at more than $100 million.
Those figures suggest Ollin is part of a broader wave of well-capitalized life sciences startups emerging from the Austin area. The city's life sciences momentum is also set to get a public spotlight this week: the Austin Business Journal is promoting an event called Austin's Health Care & Life Sciences Boom 2026, scheduled for Wednesday, featuring networking and a panel discussion on Central Texas health care and life sciences growth.
For now, the Ollin acquisition remains a signed agreement rather than a completed deal. Johnson & Johnson has said it expects the transaction to close before the end of 2026, but that timeline depends on regulatory sign-off and other customary conditions still working their way through the process.









